Key result
The cTnI(P83S) mutation blunted PKA-mediated modulation on myofibril activation and relaxation kinetics, demonstrating similar effects to other HCM-associated cTnI mutations.
The cTnI(P83S) mutation blunts PKA-mediated modulation of myofibril relaxation kinetics, similar to other HCM-associated mutations, despite its location in the I-T arm.
Answers are grounded in this paper and cite their sources.
cTnI(P83S) effects should not change practice; extends PKA-blunting mechanism to another HCM mutation in animal models.
cTnI(P82S) (cTnI(P83S) in rodents) resides at the I-T arm of cardiac troponin I (cTnI) and was initially identified as a disease-causing mutation of hypertrophic cardiomyopathy (HCM). However, later studies suggested this may not be true. We recently reported that introduction of an HCM-associated mutation in either inhibitory-peptide (cTnI(R146G)) or cardiac-specific N-terminus (cTnI(R21C)) of cTnI blunts the PKA-mediated modulation on myofibril activation/relaxation kinetics by prohibiting formation of intrasubunit contacts between these regions. Here, we tested whether this also occurs for cTnI(P83S). cTnI(P83S) increased both Ca(2+) binding affinity to cTn (KCa) and affinity of cTnC for cTnI (KC-I), and eliminated the reduction of KCa and KC-I observed for phosphorylated-cTnI(WT). In isolated myofibrils, cTnI(P83S) maintained maximal tension (TMAX) and Ca(2+) sensitivity of tension (pCa50). For cTnI(WT) myofibrils, PKA-mediated phosphorylation decreased pCa50 and sped up the slow-phase relaxation (especially for those Ca(2+) conditions that heart performs in vivo). Those effects were blunted for cTnI(P83S) myofibrils. Molecular-dynamics simulations suggested cTnI(P83S) moderately inhibited an intrasubunit interaction formation between inhibitory-peptide and N-terminus, but this "blunting" effect was weaker than that with cTnI(R146G) or cTnI(R21C). In summary, cTnI(P83S) has similar effects as other HCM-associated cTnI mutations on troponin and myofibril function even though it is in the I-T arm of cTnI.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2016) studied Hypertrophic cardiomyopathy. cTnI(P83S) mutation vs. cTnI(WT) was evaluated on Contractile properties and modulation by PKA-mediated phosphorylation. The cTnI(P83S) mutation blunted PKA-mediated modulation on myofibril activation and relaxation kinetics, demonstrating similar effects to other HCM-associated cTnI mutations.
Synapse has enriched 10 related papers. Consider them for comparative context: